

Reference: PS/OED/JM/RS/2024_02_19_CSO

Sent by email

To Global Civil Society and affected communities

Geneva, 19 February 2024

Dear Global Civil Society and affected communities,

Thank you for writing to the Global Fund and for raising these important questions. As you know, the Global Fund has played – and continues to play - a critical role in achieving affordable access to life-saving medical commodities for the poorest and most vulnerable communities in the world. The recent price reductions for anti-retroviral (ARV) medicines – taking the annual cost of treatment down to \$45 – and the 20% reduction in the price of GeneXpert TB cartridges – to \$7.98 – are examples of our ongoing efforts.

Transparency is critical to achieving our objective of affordable access, and is essential for any organization investing public money for the public good. Transparency is thus one of the Global Fund’s founding principles, and is vital to our effectiveness. So thank you for holding us accountable to that.

Our commitment to transparency, as established by the Global Fund’s Board decision GF/B03/DP15 on 10 October 2002, states “disclosure of information on prices paid for purchases by Fund Recipients is a matter of principle and will facilitate a process leading to lower prices. The Fund will ensure that information on prices paid on products of assured quality with the same conditions (e.g., including other goods or services included in the contract) is made publicly available”.

A Price and Quality Reporting mechanism (PQR) was created to make publicly available procurement transaction data. This includes supplier or manufacturer name, dosage, unit cost, packaging information, shipping or other related costs, and the total cost of transaction. See [here](#) for more details.

To achieve this, the Global Fund has included, in its framework agreements with manufacturers, the right to disclose information through the PQR. The Global Fund also publishes reference prices for key products critical for the fight against the three diseases. These reference prices are not only widely used by our grant recipients, but also by national and international buyers of health products, in particular for ARVs and antimalarial products.

However, in some circumstances, the ability for the Global Fund to disclose certain information publicly may be constrained due to legal considerations or contractual provisions. We strive to minimize such limitations, while ensuring we achieve our goal of providing affordable access to lifesaving health products to the people we serve.

Sincerely,

A handwritten signature in black ink, appearing to read 'Peter Sands', written in a cursive style.

Peter Sands
Executive Director